← Evidence map

ArticleRheumatology and therapy2026

Filgotinib in Moderate to Severe Rheumatoid Arthritis in a Real-World Setting: Up to 6-Month Effectiveness, Patient-Reported Outcomes, and Persistence, and up to 24-Month Safety from More than 1400 Patients in the FILOSOPHY and PARROTFISH Studies.

Gerd R Burmester et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

2 trials

NCT048719191,304 enrolled2021 NCT05323591155 enrolled2022

Filgotinib in Moderate to Severe Rheumatoid Arthritis in a Real-World Setting: Up to 6-Month Effectiveness, Patient-Reported Outcomes, and Persistence, and up to 24-Month Safety from More than 1400 Patients in the FILOSOPHY and PARROTFISH Studies. | OpenQuestion